Biodesix® uses highly accurate technologies to analyze circulating cell-free nucleic acids in the blood.
Identifying genomic drivers and targeting those specific alterations with therapy are a critical aspect of personalized medicine. Traditionally, this has been done through tissue-based mutation testing, but the landscape is evolving rapidly towards less invasive blood-based approaches. Tracking tumor-associated genetic aberrations in the blood can be used to quickly determine whether targeted therapies are a treatment option; assessing the response to therapy, presence of residual disease, recurrence, or relapse; and detecting the emergence of therapy-resistant cancer cells more quickly than conventional tissue-based methods.
THE BENEFITS OF LIQUID BIOPSY
“The standard prognostic procedure for cancer, the tissue biopsy, is woefully inadequate — like trying to gauge a nation’s behaviour by surveying a single street. A biopsy could miss mutations just centimetres away that might radically change a person’s chances for survival. And although biopsies can provide data about specific mutations that might make a tumour vulnerable to targeted therapies, that information is static and bound to become inaccurate as the cancer evolves.”
– ED YONG, “WRITTEN IN BLOOD”, NATURE 2014.
Droplet Digital™ PCR
Biodesix leverages Droplet Digital PCR (ddPCR™) to detect gene mutations in plasma cell-free DNA and RNA. ddPCR is highly sensitive, cost-effective, and has a fast turnaround time. Through the design of custom assays or the use of our on-market GeneStrat® test, Biodesix offers biopharma partners the ability to retrospectively analyze clinical trial samples, prospectively enroll clinical trial patients, and coordinate commercialization.